Paul B Manning bought $7.5M of Candel Therapeutics (CADL)
Executed Dec 16 2024, disclosed Dec 18 2024, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Dec 18 2024), the stock returned -1.9% (delay-adjusted); from the execution session (Dec 16 2024), +8.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Paul B Manning (Director) filed 3 Form 4 reports in the trailing twelve months (2 purchases, 1 sale, 1 filed past the two-business-day deadline), most often in Candel Therapeutics, Inc. (CADL). Across 2 priced purchase filings, the average 21-session return was +36.0% from execution and +33.7% from disclosure (delay-adjusted; derived). The largest single filing was $17.5M of VRCA (4,126,142 sh across 2 lots, as filed), executed Nov 25 2025.
Healthcare · Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→550,458 sh × $5.45
Exec Feb 23
Filed Feb 26 · 7:38 PM ET †